| abstract |
The present invention provides a method for determining the presence of prostate cancer in a subject which method comprises determining the level of expression of one or more markers in a blood sample from the subject, wherein said one or more markers comprise at least one of EM, c-met, pRB, EZH2, e-cad, CAXII, CAIX, HIF-1α, Jagged, PIM- 1, hepsin, RECK, Clusterin, MMP9, MTSP- 1, MMP24, MMP15, IGFBP-2, IGFBP-3, E2F4, caveolin, EF-1A, Kallikrein 2, Kallikrein 3 and PSGR. |